Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 2Q

Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 2Q 2Q Revenues: $5.4 billion (+3%) 2Q Earnings: $1.3 billion (+29%) YTD Revenues: $10.4 million (+3%) YTD Earnings: $2.2 billion (+17%) Comments: Revenues were up 8% excluding foreign exchange impact. Biopharmaceutical sales were $4.7 billion in the quarter (+4%). Plavix sales were $1.5 billion (+11%). Abilify sales were $643 million (+22%). Baraclude sales were $179 million (+32%). Sustiva franchise sales were $312 million (+11%). Reyataz sales were $331 mil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters